SGLT2 inhibitors, also known as sodium-glucose cotransporter-2 inhibitors, are a class of pharmaceutical drugs primarily used in the management of type 2 diabetes mellitus. These agents function by inhibiting the reabsorption of glucose in the kidneys through blockade of the sodium-glucose cotransporter-2 (SGLT2) protein, which is predominantly located in the proximal convoluted tubule of the nephron. By preventing glucose reabsorption, SGLT2 inhibitors increase urinary glucose excretion (glucosuria), thereby lowering blood glucose levels independently of insulin.
Commonly prescribed medications in this class include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. Clinical trials have demonstrated that SGLT2 inhibitors not only improve glycemic control but are also associated with additional benefits, such as modest reductions in body weight, blood pressure, and a reduced risk of major adverse cardiovascular events in patients with established cardiovascular disease. Furthermore, studies such as the EMPA-REG OUTCOME, CANVAS, and DECLARE–TIMI 58 trials have shown cardioprotective and renoprotective effects, leading to expanded indications for use in patients with heart failure and chronic kidney disease, regardless of diabetes status.
Adverse effects associated with SGLT2 inhibitors include an increased risk of urinary tract infections, genital mycotic infections, volume depletion, and, rarely, euglycemic diabetic ketoacidosis. A boxed warning has been issued by regulatory agencies, including the U.S. Food and Drug Administration (FDA), regarding the risk of necrotizing fasciitis of the perineum (Fournier’s gangrene), though this is rare.
SGLT2 inhibitors are contraindicated in patients with type 1 diabetes as monotherapy and in those with severe renal impairment, as their efficacy depends on adequate kidney function. These drugs are approved by regulatory authorities such as the FDA and the European Medicines Agency (EMA) for specific indications within diabetes and cardiovascular care.
The development and clinical application of SGLT2 inhibitors represent an advancement in diabetes pharmacotherapy due to their insulin-independent mechanism and favorable effects on multiple organ systems.